指南与共识泌尿男性生殖肿瘤

欧洲国家癌症治疗创新药物准入的争议与共识:以转移性前列腺癌为例

Controversies and consensus in the innovation access for cancer therapy in the European countries: on the subject of metastatic prostate cancer.
指南 / 共识 · Ann Oncol · 2017-01-01

本文评估了四种新药(醋酸阿比特龙、恩扎卢胺、卡巴他赛、二氯化镭-223)治疗转移性去势抵抗性前列腺癌(mCRPC)的获益程度评估差异,比较了英国、德国、法国和加拿大四国及欧洲肿瘤内科学会(ESMO)临床获益量表之间的评估结果。尽管这些药物已获欧洲药品管理局授权,但各国之间以及国家定价评估机构与ESMO之间在获益程度评估上存在明显差异,导致癌症治疗可及性不一致。作者认为应基于独立学会声明评估医学价值,并通过共同的欧洲报销和定价政策推动欧洲癌症治疗准入的协调。

要点

  • 四种mCRPC新药虽获欧洲药品管理局授权,但各国获益评估存在明显差异。
  • 国家定价评估机构与ESMO临床获益量表之间的评估结果不一致。
  • 价格设定和报销决策仍属国家职责,导致癌症治疗可及性异质。

核心结论

  • 需实施多项程序以克服行政评估的碎片化,医学价值评估应基于独立学会声明,欧洲癌症治疗准入的协调应由共同的欧洲报销和定价政策驱动。

研究设计与样本

  • 本文为指南类文章,由作者比较英国、德国、法国和加拿大四国及ESMO临床获益量表对四种mCRPC新药获益程度的评估声明。

主要发现

  • 四种新药(醋酸阿比特龙、恩扎卢胺、卡巴他赛、二氯化镭-223)已获欧洲药品管理局授权,但所选国家之间以及国家定价评估机构与ESMO之间在获益程度评估上存在明显差异。
  • 价格设定和报销决策仍属国家职责,各国对新治疗医学价值的评估存在差异,导致癌症治疗可及性异质。

关键数值与推荐

  • 比较依据为各国声明及ESMO临床获益量表,涉及药物为醋酸阿比特龙、恩扎卢胺、卡巴他赛、二氯化镭-223,用于治疗mCRPC。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Innovative cancer therapies and advances in drug development have created new hopes for patients and health providers. The purpose of this article was to evaluate the discrepancies in the assessment of the magnitude of benefit of four new drugs (abiraterone acetate, enzalutamide, cabazitaxel, radium-223 dichloride) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The comparison was done among three European countries (UK, Germany and France) and Canada, according to the statement of each country and to the European Society of Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale. Whereas those drugs are authorized by the European Medical Agency, one can observed that clear discrepancies in the magnitude of benefit assessment exist between selected countries, as well as between national pricing evaluation agencies and ESMO. However, price setting and reimbursement decisions remain national responsibility with differences in assessment of the medical value of new treatment across countries, leading to a heterogeneous accessibility to cancer treatments. In conclusion, several procedures have to be implemented to overcome the patchwork of administrative assessments. Among them, the assessment of medical value should be based on independent statements of learned societies, and the harmonization of access to cancer therapy in Europe has to be driven by a common European reimbursement and pricing policy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Oudard S, Courbon F. Controversies and consensus in the innovation access for cancer therapy in the European countries: on the subject of metastatic prostate cancer. Ann Oncol. 2017. PMID: 28426107. doi:10.1093/annonc/mdw546

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。